Glucocorticoid Therapy and Cushing Syndrome: Multimedia

References

1. Liapi C, Chrousos GP. Glucocorticoids. In: Jaffe SJ, Aranda JV, eds. Therapeutic Principles in Practice. 2^nd ed. Philadelphia, Pa: WB Saunders; 1992:466-475.

2. Lacroix A, N'Diaye N, Mircescu H, Hamet P, Tremblay J. Abnormal expression and function of hormone receptors in adrenal Cushing's syndrome. Endocr Res. Aug-Nov 1998;24(3-4):835-43. [Medline].

3. Laue L, Loriaux DL, Chrousos GP. Glucocorticoid antagonists and the role of glucocorticoids at the resting and stress state. Adv Exp Med Biol. 1988;245:225-35. [Medline].

4. Dodt C, Wellhoner JP, Schutt M, Sayk F. [Glucocorticoids and hypertension.]. Internist (Berl). Jan 2009;50(1):36-41. [Medline].

5. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet. Oct 2 1998;79(4):274-8. [Medline].

6. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res. Jan 2009;71 Suppl 1:99-104. [Medline].

7. Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K, Stratakis CA. Quality of life in children and adolescents one-year after cure of Cushing syndrome: A prospective study. Clin Endocrinol (Oxf). Dec 17 2008;[Medline].

8. Abad V, Chrousos GP, Reynolds JC, Nieman LK, Hill SC, Weinstein RS. Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. J Bone Miner Res. Oct 2001;16(10):1879-85. [Medline].

9. Agrons GA, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasms in children: radiologic-pathologic correlation. Radiographics. Jul-Aug 1999;19(4):989-1008. [Medline]. [Full Text].

10. Ansell BM. Overview of the side effects of corticosteroid therapy. Clin Exp Rheumatol. Jan-Feb 1991;9 Suppl 6:19-20. [Medline].

11. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. Dec 2003;88(12):5593-602. [Medline].

12. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. May 4 1999;130(9):759-71. [Medline]. [Full Text].

13. Chrousos GP. Glucocorticoid therapy. In: Felig P, Frohman LA, eds. Endocrinology and Metabolism. New York, NY: McGraw-Hill, Inc; 2001:609-632.

14. Curtis JA, Cormode E, Laski B, Toole J, Howard N. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child. Mar 1982;57(3):204-7. [Medline].

15. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. Jan 16 1997;336(3):172-7. [Medline].

16. Hochberg Z, Lahav M, Shen-Orr Z, Benderli A, Barzilai D. Normal values of urinary-free cortisol in children and adolescents. Isr J Med Sci. Mar 1983;19(3):286-8. [Medline].

17. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. Aug 2003;24(4):523-38. [Medline]. [Full Text].

18. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. Mar 15 1990;112(6):434-44. [Medline].

19. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. Dec 1999;84(12):4317-23. [Medline].

20. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res. Jan 2007;22(1):110-8. [Medline].

21. Magiakou MA, Chrousos GP. Corticosteroid Therapy, Nonendocrine Disease, and Corticosteroid Withdrawal. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6^th ed. St. Louis, Mo: Mosby; 1997:138-142.

22. Magiakou MA, Mastorakos G, Chrousos GP. Cushing Syndrome: Differential Diagnosis and Treatment. In: Wierman ME, ed. Diseases of the Pituitary: Diagnosis and Treatment. Totowa, NJ: Humana Press; 1997:179-202.

23. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. Sep 2006;20(3):467-82. [Medline].

24. Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. May 2005;90(5):2531-6. [Medline]. [Full Text].

25. Orth DN. Cushing's syndrome. N Engl J Med. Mar 23 1995;332(12):791-803. [Medline].

26. Orth DN. Differential diagnosis of Cushing's syndrome. N Engl J Med. Sep 26 1991;325(13):957-9. [Medline].

27. Orth DN, Kovacs WJ. The Adrenal Cortex. In: Wilson JD, Foster DW, Kronenberg H, Larsen PR, eds. Williams Textbook of Endocrinology. 9^th ed. Philadelphia, Pa: WB Saunders; 1998:517-665.

28. Papanicolaou DA, Chrousos GP. Cushing's Syndrome. In: Rakel RE, ed. Rakel's Current Therapy. Philadelphia, Pa: WB Saunders; 1999:631-637.

29. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. Mar 1982;136(3):274-5. [Medline].

30. Shepherd FA, Hoffert B, Evans WK, Emery G, Trachtenberg J. Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer. Arch Intern Med. May 1985;145(5):863-4. [Medline].

31. Tsai M-J, Clark JH, Schrader WT. Mechanisms of action of Hormones that Act as Transcription-Regulatory factors. In: Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders; 1998:55-95.

32. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. May 5 1993;269(17):2232-8. [Medline].

Further Reading

Keywords

glucocorticoid therapy, Cushing syndrome, Cushing's syndrome, CS, Cushing disease, Cushing's disease, CD, hypercortisolism, treatment, diagnosis, adrenalectomy, Nelson syndrome, multiple endocrine neoplasia type 1, MEN1, pheochromocytoma, primary pigmented nodular adrenal disease, PPNAD, McCune-Albright syndrome, adrenal cortical carcinoma, growth failure, hyperinsulinemia, insulin resistance, diabetes mellitus, peptic ulcer, pancreatitis, lymphopenia, eosinopenia, monocytopenia, sleep disturbances, insomnia, hypertension, hypokalemia, metabolic alkalosis, obesity, pubertal delay, hirsutism, hyperandrogenemia, acne, poor wound healing, cataracts, hypercalciuria, juvenile rheumatoid arthritis, JRA, anxiety, precocious puberty, lipoma, acanthosis, skin tags, tuberculosis, hypothyroidism, pseudohypoparathyroidism, Laurence-Moon syndrome, Bardet-Biedl syndrome, Smith-Magenis syndrome, Alstrom syndrome, cherubism, Prader-Willi syndrome

Contributor Information and Disclosures

Author

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London), Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece
George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Coauthor(s)

Antony Lafferty, MB ChB, FRACP, Senior Lecturer of Pediatric Endocrinology, Monash University Department of Pediatrics, National Institutes of Health, Bethesda, MD, and Princess Margaret Hospital for Children, Perth, Western Australia
Antony Lafferty, MB ChB, FRACP is a member of the following medical societies: Endocrine Society
Disclosure: Nothing to disclose.

Medical Editor

Thomas A Wilson, MD, Professor of Clinical Pediatrics, Department of Pediatrics; Director of Pediatric Endocrinology, Division of Pediatric Endocrinology, Department of Pediatrics, State University of New York at Stony Brook
Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Lynne Lipton Levitsky, MD, Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor, Department of Pediatrics, Harvard University Medical School
Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds PI, also occasional consultant

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting